(continued)
- Forzinity: New Once-Daily Shot Gets Accelerated FDA Nod for Boosting Muscle Strength in Barth Syndrome
- Keytruda Qlex: FDA Approves New Subcutaneous Immune Therapy Shot for Treating a Wide Range of Advanced Cancers
- FDA Approves At-Home Once-Weekly Leqembi Injection as Maintenance Therapy for Early Alzheimer's Disease
- Wayrilz: A New Twice-Daily Pill for Persistent and Chronic Immune Thrombocytopenia
- Papzimeos: First Approved Immunotherapy for Recurrent Respiratory Papillomatosis in Adults
- Brinsupri: First Once-Daily Tablet for Non-Cystic Fibrosis Bronchiectasis
- Hernexeos (Zongertinib) Approved as the First Oral Targeted Treatment for HER2-Mutant Advanced Lung Cancer